Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.43 |
| ▸ | PGR | P06401 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433397 | 0.83 | KDM4E (0.43) | ARPGRKDM4EL3MBTL1 | |
| SCHEMBL2430249 | 0.82 | AR (0.43) | ARPGRKDM4EL3MBTL1 | |
| SCHEMBL2427516 | 0.81 | AR (0.42) | ARPGRKDM4EALDH1A1GLA | |
| SCHEMBL2431374 | 0.80 | AR (0.46) | ARPGRKDM4EALDH1A1GLA | |
| SCHEMBL12803649 | 0.79 | KEAP1 (0.44) | PGRKDM4EALDH1A1TP53GAA | |
| SCHEMBL2429708 | 0.78 | AR (0.38) | ARPGRKDM4EALDH1A1GLA | |
| SCHEMBL2431232 | 0.77 | GHSR (0.42) | ARPGRKDM4EALDH1A1GLA | |
| SCHEMBL2431537 | 0.77 | AR (0.44) | ARPGRL3MBTL1 | |
| SCHEMBL2429403 | 0.77 | KDM4E (0.44) | ARPGRKDM4EALDH1A1GLA | |
| SCHEMBL2428161 | 0.77 | AR (0.40) | ARPGRKDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | claimed |
| US-11299457-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-04-12 | — | — | US | disclosed |
| US-20200270210-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2020-08-27 | — | — | US | disclosed |
| US-10710963-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| CN-104619693-B | The alternatively indoles nitrile of property androgen receptor modifier | 葛兰素史克知识产权第二有限公司 | 2019-08-13 | — | — | CN | disclosed |
| US-20190127326-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| US-10196353-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| EP-2875013-B1 | INDOLECARBONITRILES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| US-20170073309-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-9533948-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
| US-20200270210-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
| US-10710963-B2 | Chemical compounds | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
| US-11299457-B2 | Chemical compounds | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
| US-10196353-B2 | Chemical compounds | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | AR 1/4885PGR 48/4885KDM4E 599/4885 |
| US-20190127326-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
| US-20170073309-A1 | Chemical Compounds | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885KDM4E 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.